Question
NMIBC, muscle-invasive bladder cancer
Is there a difference in outcomes associated with sequential intravesical gemcitabine and docetaxel therapy vs bacillus Calmette-Guérin (BCG) therapy, the standard of care for the treatment of high-risk non–muscle-invasive bladder cancer (NMIBC)?